相关实验视频

Updated: Jun 11, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

在HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向HER2向H

Sushree Arpitabala Yadav¹, V Kusum Vats², Rohit Sharma²

¹Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.

Nuclear medicine and biology

|October 9, 2024

概括

逆相似A9的PEGylation改善了其循环时间和瘤吸收,以向HER2阳性乳腺癌. 这种增强的放射性对改善核医学检测和治疗有很大的希望.

科学领域:

核医学是一种核医学.
在瘤学瘤学.
放射性药物化学放射性药物化学

背景情况:

乳腺癌中人类表皮生长因子受体2 (HER2) 水平升高是一个治疗点.
复原模拟的A9显示了HER2的特异性和有利的药理动力学.
改善放射性的循环时间对于增强成像和治疗至关重要.

研究的目的:

通过PEGylation增强RL-A9放射性的循环时间.
为了评估PEGylated放射性的生物特征和疗效,使用[177Lu]Lu-DOTA-PEG12-rL-A9.9.
评估[177Lu]Lu-DOTA-PEG12-rL-A9在HER2阳性乳腺癌中用于核医学成像和治疗的潜力.

主要方法:

在RL-A9.9的N端的PEG化 (PEG12) 的固体相合成.
使用卢-177 ([177Lu]) 进行放射性标记.
在HER2表达SKBR3细胞中的体外细胞吸收研究.
在雌性SCID小鼠携带SKBR3瘤的体内生物分布研究.
阻断研究以确认受体特异性.

主要成果:

[177Lu]Lu-DOTA-PEG12-rL-A9在SKBR3细胞中表现出高特异性细胞吸收 (5.94 ± 0.09%) 和低纳米分子结合亲和力 (Kd = 34.58 ± 12.78 nM).
与非PEGylated [177Lu]Lu-DOTA-rL-A9.9相比,PEGylated放射性体在3,24和48小时内显示出较高的瘤吸收率.
阻断研究证实了放射性的特异性,瘤放射性积累减少了51%.
在PEGylated版本的48小时内,观察到瘤与胃和瘤与肠的比率有所改善.

结论:

PEGylation有效地提高了RL-A9放射性的循环时间和瘤向.
[177Lu]Lu-DOTA-PEG12-rL-A9与其非PEGylated对应物相比,显示出优越的瘤吸收和特异性.
改善的药理动力学和生物分布特征表明,HER2阳性乳腺癌的诊断和治疗应用可能会得到改善.

关键词:

在HER2中,HER2是HER2.PEG ((12)) 是一种蛋白质.在 SKBR3 中,我们可以看到:[177] Cl3) 在 rL-A9 9 的时间.

更多相关视频

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...